{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:17:04Z","timestamp":1793236624001,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cryptosporidiosis is a leading cause of severe diarrhea and mortality in young children, with no vaccine or effective treatment. A Cryptosporidium controlled human infection model (CHIM) in healthy adults provides an opportunity to evaluate the safety and efficacy of novel chemical entities prior to testing in young pediatric patients. However, CHIM development has been hindered by the lack of current Good Manufacturing Practice (cGMP)\u2013compliant Cryptosporidium parvum oocysts, which are required for filing an Investigational New Drug (IND) application with the US Food and Drug Administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To overcome this barrier, we developed a cGMP-compliant process for producing C. parvum oocysts. The approach involved sourcing well-characterized oocysts purified from neonatal calves under controlled non-GMP conditions, followed by cGMP processing that included peracetic acid\u2013based surface sanitization, comprehensive microbial testing, and release as a nonsterile oral product for human use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Peracetic acid (0.5% for 20\u2005minutes) treated C. parvum oocysts demonstrated acceptable microbial safety and preserved viability. Viability was assessed through oocyst excystation, HCT-8 cell infection, and mouse infectivity studies. The cGMP-produced C. parvum oocysts with stringent batch release test criteria for quantity, purity, identity, potency, and bioburden was released as ABO809 for clinical use under an IND. ABO809 was successfully used in human challenge studies, producing reliable infection and characteristic clinical symptoms in healthy adult volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We describe a robust cGMP-compliant and qualification process for C. parvum oocysts that enables CHIM studies in healthy adults, thereby opening avenues to evaluate efficacy of novel therapeutics and vaccines to treat cryptosporidiosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag107","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:32:16Z","timestamp":1771331536000},"source":"Crossref","is-referenced-by-count":2,"title":["Development of a Current Good Manufacturing Practice\u2013Compliant Process for Producing\n                    <i>Cryptosporidium parvum<\/i>\n                    Oocysts for Clinical Use"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-6004","authenticated-orcid":false,"given":"Rajiv S","family":"Jumani","sequence":"first","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4809-3969","authenticated-orcid":false,"given":"Bryanna","family":"Thomas","sequence":"additional","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9345-1780","authenticated-orcid":false,"given":"Jay","family":"Lakshman","sequence":"additional","affiliation":[{"name":"Technical Research and Development, Novartis Pharmaceuticals Corporation , East Hanover, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ostermeier","sequence":"additional","affiliation":[{"name":"Scientific Office DS, Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natko","family":"Nuber","sequence":"additional","affiliation":[{"name":"Analytical Project Leadership, Science & Technology , Novartis Pharma AG, Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen Hubert","family":"Blusch","sequence":"additional","affiliation":[{"name":"Scientific Office DS, Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Braud-Perez","sequence":"additional","affiliation":[{"name":"Regulatory Affairs, Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Wetty","sequence":"additional","affiliation":[{"name":"Regulatory Affairs, Novartis Pharmaceuticals Corporation , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhuo","family":"Nouaime","sequence":"additional","affiliation":[{"name":"Regulatory Affairs, Novartis Pharmaceuticals Corporation , East Hanover, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Dederichs","sequence":"additional","affiliation":[{"name":"Technical Research and Development , Novartis Pharma AG, Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Etse","sequence":"additional","affiliation":[{"name":"Technical Research and Development, Novartis Pharmaceuticals Corporation , East Hanover, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Grubesic","sequence":"additional","affiliation":[{"name":"Analytical Operations, Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-3147","authenticated-orcid":false,"given":"Suresh B","family":"Lakshminarayana","sequence":"additional","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1907-768X","authenticated-orcid":false,"given":"Lucy C","family":"Watson","sequence":"additional","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-8855","authenticated-orcid":false,"given":"Johanne","family":"Blais","sequence":"additional","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Thompson","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Biological Testing Solutions , Wayne, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq Z","family":"Jaber","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Biological Testing Solutions , Wayne, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Jones","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Biological Testing Solutions , Wayne, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-0499","authenticated-orcid":false,"given":"Deborah A","family":"Schaefer","sequence":"additional","affiliation":[{"name":"School of Animal and Comparative Biomedical Sciences, The University of Arizona , Tucson, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-6543","authenticated-orcid":false,"given":"Michael W","family":"Riggs","sequence":"additional","affiliation":[{"name":"School of Animal and Comparative Biomedical Sciences, The University of Arizona , Tucson, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-139X","authenticated-orcid":false,"given":"Christopher D","family":"Huston","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Vermont Larner College of Medicine , Burlington, Vermont ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-5683","authenticated-orcid":false,"given":"Thierry T","family":"Diagana","sequence":"additional","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-9303","authenticated-orcid":false,"given":"Ujjini H","family":"Manjunatha","sequence":"additional","affiliation":[{"name":"Global Health, Biomedical Research , Novartis, Emeryville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026031021031409100_jiag107-B1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Diarrhoeal Disease Collaborators","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026031021031409100_jiag107-B2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/acsinfecdis.9b00315","article-title":"Innovations in addressing pediatric diarrhea in low resource settings","volume":"6","author":"Jumani","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2026031021031409100_jiag107-B3","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/cid\/ciad044","article-title":"Clinical and epidemiologic features of Cryptosporidium-associated diarrheal disease among young children living in sub-Saharan Africa: the Vaccine Impact on Diarrhea in Africa (VIDA) study","volume":"76","author":"Hossain","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031021031409100_jiag107-B4","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(19)30076-2","article-title":"The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS)","volume":"7","author":"Kotloff","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2026031021031409100_jiag107-B5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"2026031021031409100_jiag107-B6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4269\/ajtmh.1999.61.707","article-title":"Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil","volume":"61","author":"Guerrant","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"2026031021031409100_jiag107-B7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","article-title":"A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium","volume":"15","author":"Checkley","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026031021031409100_jiag107-B8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","article-title":"Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial","volume":"360","author":"Amadi","year":"2002","journal-title":"Lancet"},{"key":"2026031021031409100_jiag107-B9","first-page":"CD004932","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients","volume":"1","author":"Abubakar","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026031021031409100_jiag107-B10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41564-024-01810-x","article-title":"Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis","volume":"9","author":"Manjunatha","year":"2024","journal-title":"Nat Microbiol"},{"key":"2026031021031409100_jiag107-B11","doi-asserted-by":"crossref","first-page":"e012540","DOI":"10.1136\/bmjgh-2023-012540","article-title":"Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease","volume":"8","author":"Gilbert","year":"2023","journal-title":"BMJ Glob Health"},{"key":"2026031021031409100_jiag107-B12","doi-asserted-by":"crossref","first-page":"e0013263","DOI":"10.1371\/journal.pntd.0013263","article-title":"Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1","volume":"19","author":"Choi","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"key":"2026031021031409100_jiag107-B13","author":"US Food and Drug Administration","year":"2022"},{"key":"2026031021031409100_jiag107-B14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/ciaa421","article-title":"Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial","volume":"73","author":"Iroh Tam","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026031021031409100_jiag107-B15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1021\/acsinfecdis.1c00057","article-title":"Opportunities and challenges in developing a Cryptosporidium controlled human infection model for testing antiparasitic agents","volume":"7","author":"Jumani","year":"2021","journal-title":"ACS Infect Dis"},{"key":"2026031021031409100_jiag107-B16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026031021031409100_jiag107-B17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM199503303321304","article-title":"The infectivity of Cryptosporidium parvum in healthy volunteers","volume":"332","author":"DuPont","year":"1995","journal-title":"N Engl J Med"},{"key":"2026031021031409100_jiag107-B18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/IAI.66.2.441-443.1998","article-title":"Susceptibility and serologic response of healthy adults to reinfection with Cryptosporidium parvum","volume":"66","author":"Okhuysen","year":"1998","journal-title":"Infect Immun"},{"key":"2026031021031409100_jiag107-B19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4269\/ajtmh.1999.60.157","article-title":"Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G","volume":"60","author":"Chappell","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"2026031021031409100_jiag107-B20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/315033","article-title":"Virulence of three distinct Cryptosporidium parvum isolates for healthy adults","volume":"180","author":"Okhuysen","year":"1999","journal-title":"J Infect Dis"},{"key":"2026031021031409100_jiag107-B21","author":"US Food and Drug Administration","year":"2013"},{"key":"2026031021031409100_jiag107-B22","author":"US Food and Drug Administration","year":"2008"},{"key":"2026031021031409100_jiag107-B23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4939-9748-0_15","article-title":"Calf clinical model of cryptosporidiosis for efficacy evaluation of therapeutics","volume":"2052","author":"Riggs","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2026031021031409100_jiag107-B24","first-page":"56S","article-title":"Cryptosporidium parvum: synchronized excystation in vitro and evaluation of sporozoite infectivity with a new lectin-based assay","volume":"46","author":"Gut","year":"1999","journal-title":"J Eukaryotic Microbiol"},{"key":"2026031021031409100_jiag107-B25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3201\/eid0806.010368","article-title":"Three drinking-water-associated cryptosporidiosis outbreaks, Northern Ireland","volume":"8","author":"Glaberman","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"2026031021031409100_jiag107-B26","author":"United States Pharmacopeia\u2013National Formulary","year":"2009"},{"key":"2026031021031409100_jiag107-B27","author":"United States Pharmacopeia\u2013National Formulary","year":"2009"},{"key":"2026031021031409100_jiag107-B28","author":"United States Pharmacopeia\u2013National Formulary","year":"2009"},{"key":"2026031021031409100_jiag107-B29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-031-66074-0_7","volume-title":"Peracetic acid. Antiseptic stewardship: biocide resistance and clinical implications","author":"Kampf","year":"2024"},{"key":"2026031021031409100_jiag107-B30","author":"Centers for Disease Control and Prevention","year":"2008"},{"key":"2026031021031409100_jiag107-B31","author":"US Food and Drug Administration"},{"key":"2026031021031409100_jiag107-B32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0016-5107(99)70389-5","article-title":"Inactivation of Cryptosporidium parvum oocyst infectivity by disinfection and sterilization processes","volume":"49","author":"Barbee","year":"1999","journal-title":"Gastrointest Endosc"},{"key":"2026031021031409100_jiag107-B33","author":"US Food and Drug Administration"},{"key":"2026031021031409100_jiag107-B34","author":"US Food and Drug Administration","year":"2024"},{"key":"2026031021031409100_jiag107-B35","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1128\/JCM.36.9.2503-2508.1998","article-title":"The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum","volume":"36","author":"Griffiths","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2026031021031409100_jiag107-B36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"Manjunatha","year":"2017","journal-title":"Nature"},{"key":"2026031021031409100_jiag107-B37","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/s41467-019-09880-w","article-title":"A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors","volume":"10","author":"Jumani","year":"2019","journal-title":"Nat Commun"},{"key":"2026031021031409100_jiag107-B38","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"Baragana","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031021031409100_jiag107-B39","doi-asserted-by":"crossref","first-page":"e01505-17","DOI":"10.1128\/AAC.01505-17","article-title":"A novel piperazine-based drug lead for cryptosporidiosis from the Medicines for Malaria Venture open access malaria box","volume":"62","author":"Jumani","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031021031409100_jiag107-B40","doi-asserted-by":"crossref","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","article-title":"A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis","volume":"11","author":"Love","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2026031021031409100_jiag107-B41","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1038\/s41467-019-10687-y","article-title":"Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis","volume":"10","author":"Lunde","year":"2019","journal-title":"Nat Commun"},{"key":"2026031021031409100_jiag107-B42","author":"Stuart"},{"key":"2026031021031409100_jiag107-B43","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1038\/s41467-018-05240-2","article-title":"Cryopreservation of infectious Cryptosporidium parvum oocysts","volume":"9","author":"Jaskiewicz","year":"2018","journal-title":"Nat Commun"},{"key":"2026031021031409100_jiag107-B44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1126\/science.1094786","article-title":"Complete genome sequence of the apicomplexan, Cryptosporidium parvum","volume":"304","author":"Abrahamsen","year":"2004","journal-title":"Science"},{"key":"2026031021031409100_jiag107-B45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/nature02977","article-title":"The genome of Cryptosporidium hominis","volume":"431","author":"Xu","year":"2004","journal-title":"Nature"},{"key":"2026031021031409100_jiag107-B46","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","article-title":"Experimental infection of human volunteers","volume":"18","author":"Roestenberg","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026031021031409100_jiag107-B47","doi-asserted-by":"crossref","first-page":"e0000821","DOI":"10.1128\/cmr.00008-21","article-title":"Controlled human infection models to accelerate vaccine development","volume":"35","author":"Choy","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2026031021031409100_jiag107-B48","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026031021031409100_jiag107-B49","doi-asserted-by":"crossref","first-page":"e0009969","DOI":"10.1371\/journal.pntd.0009969","article-title":"A phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model","volume":"15","author":"Erdem","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2026031021031409100_jiag107-B50","doi-asserted-by":"crossref","first-page":"e00479-17","DOI":"10.1128\/IAI.00479-17","article-title":"Controlled human malaria infection: applications, advances, and challenges","volume":"86","author":"Stanisic","year":"2018","journal-title":"Infect Immun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag107\/66981973\/jiag107.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag107\/66981973\/jiag107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:03:22Z","timestamp":1773191002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag107\/8489949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag107","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"jiag107"}}